Spots Global Cancer Trial Database for v503
Every month we try and update this database with for v503 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | NCT02653118 | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papilloma... | V503 GARDASIL | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | NCT01047345 | Cervical Cancer... Vulvar Cancers Vaginal Cancers Genital Warts | V503 Placebo to V503 | 12 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | NCT00943722 | Cervical Cancer... Vulvar Cancer Vaginal Cancer Genital Lesions PAP Test Abnorm... HPV Infections | V503 | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) | NCT02114385 | Papilloma Viral... | V503 GARDASIL | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | NCT00943722 | Cervical Cancer... Vulvar Cancer Vaginal Cancer Genital Lesions PAP Test Abnorm... HPV Infections | V503 | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) | NCT00988884 | Human Papilloma... | V503 Comparator: Men... Comparator: Ada... Comparator: Men... Comparator: Ada... | 11 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | NCT03903562 | Papillomavirus ... | V503 | 9 Years - 45 Years | Merck Sharp & Dohme LLC | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | NCT03158220 | Cervical Cancer Vulvar Cancer Vaginal Cancer Genital Warts Human Papilloma... | V503 | 16 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | NCT03998254 | Papillomavirus ... | V503 Gardasil | 20 Years - 45 Years | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
